Eisai Europe
Eisai Europe Limited, a subsidiary of the global pharmaceutical company Eisai Co., Ltd., is headquartered in Great Britain and operates extensively across Europe. Founded in 1941, Eisai has established itself as a leader in the pharmaceutical industry, focusing on neurology and oncology. The company is renowned for its innovative products, including treatments for Alzheimer’s disease and various cancers, which are distinguished by their patient-centric approach and commitment to improving quality of life. With a strong market position, Eisai Europe has achieved significant milestones, including the development of groundbreaking therapies that address unmet medical needs. The company’s dedication to research and development, combined with its collaborative partnerships, underscores its role as a key player in advancing healthcare solutions across the continent.
DitchCarbon Score
How does Eisai Europe's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai Europe's score of 51 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eisai Europe's reported carbon emissions
In 2023, Eisai Europe reported total carbon emissions of approximately 2,049,450 kg CO2e, with emissions distributed across various scopes: 2,049,450 kg CO2e for Scope 1, 1,647,600 kg CO2e for Scope 2, and 37,640 kg CO2e for Scope 3. This represents a significant reduction from their 2020 emissions of about 4,479,200 kg CO2e, indicating a proactive approach to climate action. Eisai Europe has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across their entire value chain by FY2045. They have established near-term targets to reduce absolute Scope 1 and 2 emissions by 62% by FY2032, using FY2022 as the baseline. Additionally, they plan to cut Scope 3 emissions by 41% within the same timeframe. The company is also committed to sourcing 100% renewable electricity by FY2030, up from 98% in FY2022. These initiatives align with industry standards for climate action, demonstrating Eisai Europe's dedication to sustainability and reducing their carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,052,700 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,617,600 | 0,000,000 | 0,000,000 |
| Scope 3 | 789,700 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai Europe is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
